Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1
Genentech has reported late-breaking Phase III data from the FENtrepid trial showing that its investigational Bruton’s tyrosine kinase inhibitor fenebrutinib achieved non-inferiority to ocrelizumab in reducing disability progression in patients with primary progressive multiple sclerosis. The results were presented at the ACTRIMS Forum 2026 and position fenebrutinib as the first oral, brain-penetrant therapy to directly
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.
Find out how Johnson & Johnson’s CHMP opinion for AKEEGA could shift prostate cancer treatment toward earlier, biomarker-guided precision therapy.
Discover how Idorsia Pharmaceuticals Ltd’s FDA-aligned Phase 3 plan could make lucerastat the first oral therapy for all Fabry disease patients. Read the analysis.
Pulmovant completes PHocus enrollment for mosliciguat in PH-ILD. Find out what this milestone really means ahead of 2026 clinical data.
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.
Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.
Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.